SIMULTANEOUS MONITORING OF LEVODOPA, DOPAMINE AND THEIR METABOLITES IN SKELETAL-MUSCLE AND SUBCUTANEOUS TISSUE IN DIFFERENT PHARMACOLOGICAL CONDITIONS USING MICRODIALYSIS

被引:14
作者
DELEU, D [1 ]
SARRE, S [1 ]
EBINGER, G [1 ]
MICHOTTE, Y [1 ]
机构
[1] VRIJE UNIV BRUSSELS,INST PHARMACEUT,DEPT PHARMACEUT CHEM & DRUG ANAL,B-1050 BRUSSELS,BELGIUM
关键词
LEVODOPA; DOPAMINE; MICRODIALYSIS; SUBCUTANEOUS TISSUE; MUSCLE;
D O I
10.1016/0731-7085(93)80008-O
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Microdialysis, in combination with ion-pair reversed-phase liquid chromatography and electrochemical detection is described for the simultaneous determination of levodopa, dopamine, 3-O-methyldopa and 3,4-dihydroxyphenylacetic acid in the extracellular space of skeletal muscle and subcutaneous tissue in vivo in beagle dog. The relative recoveries in vitro for levodopa, dopamine, 3-O-methyldopa and 3,4-dihydroxyphenylacetic acid with a 16 mm probe at a flow rate of 5 mul min-1 were 29.1, 25.1, 34.7 and 30. 1 %, respectively. This technique was then applied for three types of pharmacological experiments. In the first experiment L-dopa was administered without carbidopa pretreatment, in the second one, L-dopa was administered following carbidopa pretreatment, and in the last experiment, following pretreatment with both carbidopa and the catechol-O-methyltransferase inhibitor, OR-611. After the administration of levodopa without carbidopa pretreatment, all four compounds could be detected in dialysates from skeletal muscle, whereas dopamine and 3,4-dihydroxyphenylacetic acid were not found in dialysates from subcutaneous tissue. After the administration of levodopa following carbidopa pretreatment and following pretreatment with both carbidopa and OR-611 all compounds could be measured except for dopamine. This method enables the pharmacokinetics and metabolism of levodopa to be studied in subcutaneous tissue and skeletal muscle simultaneously.
引用
收藏
页码:577 / 585
页数:9
相关论文
共 19 条
[1]   EFFECT OF SUPPLEMENTAL CARBIDOPA ON BIOAVAILABILITY OF L-DOPA [J].
CEDARBAUM, JM ;
KUTT, H ;
DHAR, AK ;
WATKINS, S ;
MCDOWELL, FH .
CLINICAL NEUROPHARMACOLOGY, 1986, 9 (02) :153-159
[2]   EFFECT OF NITECAPONE (OR-462) ON THE PHARMACOKINETICS OF LEVODOPA AND 3-O-METHYLDOPA FORMATION IN CYNOMOLGUS MONKEYS [J].
CEDARBAUM, JM ;
LEGER, G ;
RECHES, A ;
GUTTMAN, M .
CLINICAL NEUROPHARMACOLOGY, 1990, 13 (06) :544-552
[3]   REDUCTION OF CIRCULATING 3-O-METHYLDOPA BY INHIBITION OF CATECHOL-O-METHYLTRANSFERASE WITH OR-611 AND OR-462 IN CYNOMOLGUS MONKEYS - IMPLICATIONS FOR THE TREATMENT OF PARKINSONS-DISEASE [J].
CEDARBAUM, JM ;
LEGER, G ;
GUTTMAN, M .
CLINICAL NEUROPHARMACOLOGY, 1991, 14 (04) :330-342
[4]   CLINICAL PHARMACOKINETICS OF ANTI-PARKINSONIAN DRUGS [J].
CEDARBAUM, JM .
CLINICAL PHARMACOKINETICS, 1987, 13 (03) :141-178
[5]  
DELEU D, 1991, N-S ARCH PHARMACOL, V344, P514
[6]   CONTINUOUS INTRAVENOUS MONITORING OF LEVODOPA AND 3-O-METHYLDOPA BY MICRODIALYSIS AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION [J].
DELEU, D ;
SARRE, S ;
HERREGODTS, P ;
EBINGER, G ;
MICHOTTE, Y .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1991, 9 (02) :159-165
[7]   CLINICAL AND PHARMACOKINETIC COMPARISON OF ORAL AND DUODENAL DELIVERY OF LEVODOPA CARBIDOPA IN PATIENTS WITH PARKINSONS-DISEASE WITH A FLUCTUATING RESPONSE TO LEVODOPA [J].
DELEU, D ;
EBINGER, G ;
MICHOTTE, Y .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (05) :453-458
[8]   LEVODOPA [J].
DELEU, D .
LANCET, 1992, 339 (8786) :189-189
[9]  
Jaffe ME, 1973, ADV NEUROL, V2, P161
[10]  
KOPIN IJ, 1985, PHARMACOL REV, V37, P333